Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,044 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.
Okines AFC, Curigliano G, Mizuno N, Oh DY, Rorive A, Soliman H, Takahashi S, Bekaii-Saab T, Burkard ME, Chung KY, Debruyne PR, Fox JR, Gambardella V, Gil-Martin M, Hamilton EP, Monk BJ, Nakamura Y, Nguyen D, O'Malley DM, Olawaiye AB, Pothuri B, Reck M, Sudo K, Sunakawa Y, Van Marcke C, Yu EY, Ramos J, Tan S, Bieda M, Stinchcombe TE, Pohlmann PR. Okines AFC, et al. Among authors: hamilton ep. Nat Med. 2025 Jan 17. doi: 10.1038/s41591-024-03462-0. Online ahead of print. Nat Med. 2025. PMID: 39825152
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.
Lakhani NJ, Stewart D, Richardson DL, Dockery LE, Van Le L, Call J, Rangwala F, Wang G, Ma B, Metenou S, Huguet J, Offman E, Pandite L, Hamilton E. Lakhani NJ, et al. Among authors: hamilton e. J Immunother Cancer. 2025 Jan 11;13(1):e010565. doi: 10.1136/jitc-2024-010565. J Immunother Cancer. 2025. PMID: 39800375 Free PMC article. Clinical Trial.
Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial.
Dennis N, Dunton K, Livings C, Bogoeva N, Bourke S, Oluboyede Y, Hamilton E, Iwata H, Cortés J. Dennis N, et al. Among authors: hamilton e. Eur J Cancer. 2024 Dec 26;217:115192. doi: 10.1016/j.ejca.2024.115192. Online ahead of print. Eur J Cancer. 2024. PMID: 39798264 Free article.
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03.
Dowlati A, Chiang AC, Cervantes A, Babu S, Hamilton E, Wong SF, Tazbirkova A, Sullivan IG, van Marcke C, Italiano A, Patel J, Mekan S, Wu T, Waqar SN. Dowlati A, et al. Among authors: hamilton e. J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02549-8. doi: 10.1016/j.jtho.2024.12.028. Online ahead of print. J Thorac Oncol. 2025. PMID: 39755168 Free article.
Is trauma associated with plant-based diet choice?
Nomamiukor FO, Smethurst MA, Franz MR, Hamilton EG, Garza A, Padilla-Medina D, Davis M, Taft CT. Nomamiukor FO, et al. Among authors: hamilton eg. Appetite. 2024 Dec 24;206:107841. doi: 10.1016/j.appet.2024.107841. Online ahead of print. Appetite. 2024. PMID: 39725065
1,044 results